AML, MDS, or ALL

After Transplant

Criteria to qualify for study: Drug used in study:
  • Patients must have documented FLT3 ITD mutation
  • Patient must have undergone allo transplant in CR1 with Bu/Flu, Flu/Mel, Bu/Cy or Cy/TBI
  • Recovery of counts by Day 42
  • ANC>1000 & PLT > 20

SCRI AML-17
A Phase II, Randomized, Comparative Trial of Standard of Care, With or Without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia

 

 

 

 

 

 


ALL - Relapsed or Refactory 

Criteria to qualify for study: Drug used in study:
  • >5% and <30% blasts
  • <20K peripheral blasts
  • Progression at any time after receiving single agent azacitidine or decitabine.
  • Relapse after initial CR or PR after receiving single agent azacitidine or decitabine
  • —Failure to achieve a response after at least 6 cycles of azacitidine or 4 cycles of decitabine

SCRI MDS-15

A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethlating Agesnt (HMA) in Patients with Myelodysplastic Syndrome (MDS) Who Have Faild to Respond or Maintain a Response to the HMA Alone

 

 

 

 

 

 

 

 


AML - Relapsed or Refractory

No Current Studies


AML Treatment Naive

Criteria to qualify for study: Drug used in study:
  • ŸAge 60 years or older
  • ŸNo prior treatment.
  • Unlikely to benefit from    
        standard induction therapy

      Exclusions:

  • Known favorable cytogenetic risk.
  • WBC count >50K
  • Hepatic impairment
  • Treatment with CYP3A inducers /
        inhibitors within 14 days of treatment

Millennium C15009 - CBCI-245

A Phase 1b, Open-Label, Dose-Escalation Study of MLN4924 Plus Azacitidine in Treatment-Naive Patients With Acute Myelogenous Leukemia Who Are 60 Year or Older.



 

 

 

 

 

 

 

 


MDS Untreated

Criteria to qualify for study: Drug used in study:
  •  >5% and <30% blasts
  • <20K peripheral blasts
  • No treatment within the last 21 days.
  • No CNS disease
  • Bone marrow biopsy done within 28 days and slides must be available

 SCRI MDS-14

A Phase II Randomized, Double-Blinded, Placebo-Controlled Study of Pracinostat in Combination with Azacitidine in Patients with Previously Untreated International Prognostic Scoring System (IPSS) Intermediate Risk 2 or High-Risk Myelodysplastic Syndrome (MDS)